Clinical Trials ·
The study investigates the safety and tolerability of LY3437943, a formulation of Retatrutide, in Chinese participants with obesity or overweight. The research aims to understand how the body processes this medication and its overall effects. With a duration of approximately 20 weeks, the study involves multiple visits for participants receiving either the drug or a placebo.
What this source covers
This clinical trial, registered under NCT05548231, focuses on evaluating LY3437943 in individuals with a body mass index (BMI) indicative of overweight or obesity. Participants will undergo blood tests to assess the pharmacokinetics and pharmacodynamics of the drug. The study is structured to include around 20 visits to the study center, excluding the screening period.
Why it matters for Retatrutide research
The findings from this trial are crucial for understanding Retatrutide's safety profile, particularly in a specific demographic. As obesity continues to be a significant public health challenge, insights from this study could inform future research and therapeutic strategies targeting weight management. The focus on a Chinese cohort also adds valuable data to the global understanding of Retatrutide's effects across different populations.
Key findings or claims
- The study aims to evaluate the safety and tolerability of LY3437943 in participants with obesity or overweight.
- Blood tests will be conducted to understand how the body processes the drug.
- Participants will receive either LY3437943 or a placebo via subcutaneous injections.
- The study duration is approximately 20 weeks, with up to 20 visits required.
- The trial specifically targets Chinese participants, adding to the diversity of research data.
Context and prior work
Retatrutide, a dual agonist of GLP-1 and GIP, has been studied for its potential in weight management and metabolic health. Previous research has indicated that GLP-1 receptor agonists can lead to significant weight loss and improved metabolic markers. This trial contributes to the growing body of literature examining the efficacy and safety of Retatrutide, particularly in diverse populations. Understanding its effects in different ethnic groups is essential for tailoring obesity treatments effectively.
Practical takeaways for researchers
This study highlights the importance of ongoing research into the safety and efficacy of Retatrutide in various populations. Researchers should consider the implications of demographic factors when interpreting trial results. The findings may also guide future studies on dosing, long-term effects, and comparative efficacy against other weight-loss medications. For those interested in further exploring Retatrutide's potential, resources such as the Ultimate Guide to Peptide Stacking and the Buyers Guide may provide additional insights.
FAQ
What is LY3437943?
LY3437943 is a formulation of Retatrutide being evaluated for its safety and tolerability in individuals with obesity or overweight.
How long will the study last?
The study is expected to last approximately 20 weeks, excluding the screening period.
Who are the participants in this study?
The study focuses on Chinese participants with a body mass index indicative of overweight or obesity.
Source: ClinicalTrials.gov · NCT05548231 · published 2023-08-14.